Lupin has launched Fluoxetine Tablets USP, 60mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen Group Holdings 3 LLC’s Fluoxetine Tablets, 60mg.
It is indicated in the treatment of Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Bulimia Nervosa and panic disorder, with or without agoraphobia. Fluoxetine Tablets, 60mg, had annual sales of approximately $41 million in the US (IQVIA MAT February 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
